Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 Jan 23;17(1):13.
doi: 10.1186/s13075-015-0522-8.

Epidemiology and Management of Gout in Taiwan: A Nationwide Population Study

Free PMC article

Epidemiology and Management of Gout in Taiwan: A Nationwide Population Study

Chang-Fu Kuo et al. Arthritis Res Ther. .
Free PMC article


Introduction: Gout is the most common inflammatory arthritis worldwide and is the only type of chronic arthritis that potentially can be 'cured'. However, data on gout incidence, prevalence and management, assessed at multiple time points in the same population, are sparse, particularly in Asian populations. The aim of this study was to describe trends in the epidemiology of gout in the general population of Taiwan.

Methods: The National Health Insurance Research Database was used to identify patients with gout and to estimate the prevalence and incidence of gout for each calendar year from 2005 to 2010. The pattern of gout management was also examined.

Results: Of 23,371,362 beneficiaries in 2010, there were 1,458,569 prevalent and 56,595 incident cases of gout, giving a prevalence of 6.24% (95% confidence interval (CI), 6.23% to 6.25%) and an incidence of 2.74 (95% CI, 2.72 to 2.76) per 1,000 person-years. The annual percentage change (APC) of the standardised prevalence was -0.7% (95% CI, -1.7% to 0.3%; P=0.14), suggesting that the prevalence of gout was essentially the same throughout the study period. However, The APC of incidence was -13.4 (95% CI, -16.1 to -10.6) between 2005 and 2007 and -2.1 (95% CI, -10.4 to 7.1) between 2007 and 2010. Regions with the highest prevalence and incidence were eastern coastal counties and offshore islets, where indigenous people are clustered. Among prevalent gout cases in 2010, only 22.93% (95% CI, 22.87% to 23.00%) were prescribed urate-lowering treatment (ULT), which remained unchanged between 2005 and 2010 at an APC of 0.0 (95% CI, -3.8 to 4.0). Uricosuric agents were more commonly prescribed than xanthine oxidase inhibitors in Taiwan.

Conclusions: In Taiwan, 1 in 16 people have gout. Whereas the incidence has decreased recently, the prevalence remains unchanged. Management of gout in Taiwan is poor, with only one in five affected people being treated with ULT.


Figure 1
Figure 1
Age-specific prevalence (a) and incidence (b) of gout in Taiwan in 2010. Blue: men; red: women.
Figure 2
Figure 2
Differences by sex in the trends of standardised prevalence (a) and incidence (b) of gout in Taiwan between 2005 and 2010. Blue: men; red: women; green: overall).
Figure 3
Figure 3
Geographic variation in the prevalence (a) and incidence (b) of gout in Taiwan in 2010.
Figure 4
Figure 4
Secular trends of treatment of gout in Taiwan. Proportion of prevalent gout cases in which patients received consultations for gout or underwent urate-lowering treatment (black line), only received urate-lowering treatment (black dotted line), received uricosuric agents (red line), received a xanthine oxidase inhibitor (blue line) or received both (green line).

Similar articles

See all similar articles

Cited by 30 articles

See all "Cited by" articles


    1. Smith E, Hoy D, Cross M, Merriman TR, Vos T, Buchbinder R, et al. The global burden of gout: estimates from the Global Burden of Disease 2010 study. Ann Rheum Dis. 2014;73:1470–6. doi: 10.1136/annrheumdis-2013-204647. - DOI - PubMed
    1. Wortmann RL, Schumacher HR, Becker MA, Ryan LM, editors. Crystal-induced arthropathies: gout, pseudogout, and apatite-associated syndromes. New York: Taylor & Francis; 2006.
    1. Doherty M, Jansen TL, Nuki G, Pascual E, Perez-Ruiz F, Punzi L, et al. Gout: why is this curable disease so seldom cured? Ann Rheum Dis. 2012;71:1765–70. doi: 10.1136/annrheumdis-2012-201687. - DOI - PubMed
    1. Kuo CF, Yu KH, See LC, Chou IJ, Tseng WY, Chang HC, et al. Elevated risk of mortality among gout patients: a comparison with the national population in Taiwan. Joint Bone Spine. 2011;78:577–80. doi: 10.1016/j.jbspin.2011.01.007. - DOI - PubMed
    1. Kuo CF, See LC, Luo SF, Ko YS, Lin YS, Hwang JS, et al. Gout: an independent risk factor for all-cause and cardiovascular mortality. Rheumatology (Oxford) 2010;49:141–6. doi: 10.1093/rheumatology/kep364. - DOI - PubMed

Publication types